Monday, April 29, 2013 6:23:12 PM
Got this over at Yahoo MB,comments??
Battelle contract goal is an IDE device for sepsis.
by investa_gator1 • 15 minutes ago Flag
If AEMD obtains the IDE FDA go ahead it would also support the Battelle contract goal for an IDE device for sepsis. That would be a real feather in their cap. The only thing holding the FDA back from granting any device IDE testing, is the assurance that any device is safe enough for use, FDA is 1 in 10 million use cycles. The biggest issue is how does the HP stop any of the fiber doping materials from entering the blood stream and that the delta pressures from the dialysis machines don't over pressure the HP device and cause failures. The HP filter should not have any problems if the dialysis machines operate properly. What measures has AEMD devised to insure that the over pressuring can not occur. This is an interesting problem.
Battelle contract goal is an IDE device for sepsis.
by investa_gator1 • 15 minutes ago Flag
If AEMD obtains the IDE FDA go ahead it would also support the Battelle contract goal for an IDE device for sepsis. That would be a real feather in their cap. The only thing holding the FDA back from granting any device IDE testing, is the assurance that any device is safe enough for use, FDA is 1 in 10 million use cycles. The biggest issue is how does the HP stop any of the fiber doping materials from entering the blood stream and that the delta pressures from the dialysis machines don't over pressure the HP device and cause failures. The HP filter should not have any problems if the dialysis machines operate properly. What measures has AEMD devised to insure that the over pressuring can not occur. This is an interesting problem.
Recent AEMD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:18 PM
- Advancements in Novel Immunotherapeutics in The Oncology Battle • Newsfile • 03/24/2026 02:30:00 PM
- Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review • PR Newswire (US) • 03/24/2026 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 01:15:09 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities • PR Newswire (US) • 03/12/2026 12:01:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th • GlobeNewswire Inc. • 03/06/2026 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:15:32 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 02:54:05 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/18/2026 01:22:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 10:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:15:44 PM
- Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update • PR Newswire (US) • 02/12/2026 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 • PR Newswire (US) • 02/04/2026 01:01:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/27/2026 09:15:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/27/2026 09:15:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2026 10:15:32 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/16/2026 10:14:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/16/2026 09:15:44 PM
